99 related articles for article (PubMed ID: 19666866)
21. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
Kim SJ; Yoon DH; Kang HJ; Hong JY; Lee HS; Oh SY; Shin HJ; Kong JH; Yi JH; Sakamoto K; Ko YH; Huh J; Lee SS; Takeuchi K; Shin DY; Suh C; Kim WS
BMC Cancer; 2019 Nov; 19(1):1080. PubMed ID: 31707975
[TBL] [Abstract][Full Text] [Related]
22. Major Effect of Oxidative Stress on the Male, but Not Female, SP-A1 Type II Cell miRNome.
Noutsios GT; Thorenoor N; Zhang X; Phelps DS; Umstead TM; Durrani F; Floros J
Front Immunol; 2019; 10():1514. PubMed ID: 31354704
[TBL] [Abstract][Full Text] [Related]
23. Deregulation of miRNA in
Blosse A; Levy M; Robe C; Staedel C; Copie-Bergman C; Lehours P
J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31200531
[TBL] [Abstract][Full Text] [Related]
24. Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing.
Agnelli L; Bisognin A; Todoerti K; Manzoni M; Taiana E; Galletti S; Cutrona G; Gaffo E; Bortoluzzi S; Neri A
Blood Cancer J; 2019 Feb; 9(3):21. PubMed ID: 30783080
[TBL] [Abstract][Full Text] [Related]
25. Preliminary study on the effect of nucleolin specific aptamer-miRNA let-7d chimera on Janus kinase-2 expression level and activity in gastric cancer (MKN-45) cells.
Ramezanpour M; Daei P; Tabarzad M; Khanaki K; Elmi A; Barati M
Mol Biol Rep; 2019 Feb; 46(1):207-215. PubMed ID: 30415442
[TBL] [Abstract][Full Text] [Related]
26. Abnormal microRNA expression in the course of hematological malignancies.
Szymczyk A; Macheta A; Podhorecka M
Cancer Manag Res; 2018; 10():4267-4277. PubMed ID: 30349361
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs as Biomarkers of B-cell Lymphoma.
Solé C; Arnaiz E; Lawrie CH
Biomark Insights; 2018; 13():1177271918806840. PubMed ID: 30349178
[TBL] [Abstract][Full Text] [Related]
28. MiRNA Dysregulation in Childhood Hematological Cancer.
Carvalho de Oliveira J; Molinari Roberto G; Baroni M; Bezerra Salomão K; Alejandra Pezuk J; Sol Brassesco M
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30201877
[TBL] [Abstract][Full Text] [Related]
29. Tumor-suppressive miRNA-135a inhibits breast cancer cell proliferation by targeting ELK1 and ELK3 oncogenes.
Ahmad A; Zhang W; Wu M; Tan S; Zhu T
Genes Genomics; 2018 Mar; 40(3):243-251. PubMed ID: 29892795
[TBL] [Abstract][Full Text] [Related]
30. Analysis of NFKB2‑mediated regulation of mechanisms underlying the development of Hodgkin's lymphoma.
Zhang Y; Tong L; Chen S; Wu W; Wang L
Mol Med Rep; 2018 Jun; 17(6):8129-8136. PubMed ID: 29693141
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA expression profiling in placenta and maternal plasma in early pregnancy loss.
Hosseini MK; Gunel T; Gumusoglu E; Benian A; Aydinli K
Mol Med Rep; 2018 Apr; 17(4):4941-4952. PubMed ID: 29393376
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
Van Den Neste E; André M; Gastinne T; Stamatoullas A; Haioun C; Belhabri A; Reman O; Casasnovas O; Ghesquieres H; Verhoef G; Claessen MJ; Poirel HA; Copin MC; Dubois R; Vandenberghe P; Stoian IA; Cottereau AS; Bailly S; Knoops L; Morschhauser F
Haematologica; 2018 May; 103(5):840-848. PubMed ID: 29351986
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-135a is involved in podocyte injury in a transient receptor potential channel 1-dependent manner.
Yang X; Wu D; Du H; Nie F; Pang X; Xu Y
Int J Mol Med; 2017 Nov; 40(5):1511-1519. PubMed ID: 28949388
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic effects of long-circulating miR-135a-containing cationic immunoliposomes against gallbladder carcinoma.
Yang G; Yin B
Sci Rep; 2017 Jul; 7(1):5982. PubMed ID: 28729631
[TBL] [Abstract][Full Text] [Related]
35. Non-Coding RNAs in Hodgkin Lymphoma.
Cordeiro A; Monzó M; Navarro A
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28555062
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Gravelle P; Burroni B; Péricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; Fournié JJ; Laurent C
Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
[TBL] [Abstract][Full Text] [Related]
37. High-throughput sequencing of pituitary and hypothalamic microRNA transcriptome associated with high rate of egg production.
Wu N; Zhu Q; Chen B; Gao J; Xu Z; Li D
BMC Genomics; 2017 Mar; 18(1):255. PubMed ID: 28335741
[TBL] [Abstract][Full Text] [Related]
38. Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53.
Malpeli G; Barbi S; Zupo S; Tosadori G; Scardoni G; Bertolaso A; Sartoris S; Ugel S; Vicentini C; Fassan M; Adamo A; Krampera M; Scupoli MT; Croce CM; Scarpa A
Oncotarget; 2017 Feb; 8(7):11809-11826. PubMed ID: 28107180
[TBL] [Abstract][Full Text] [Related]
39. Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways.
Benzina S; Harquail J; Guerrette R; O'Brien P; Jean S; Crapoulet N; Robichaud GA
J Cancer; 2016; 7(14):2035-2044. PubMed ID: 28070224
[TBL] [Abstract][Full Text] [Related]
40. miRNA-135a promotes hepatocellular carcinoma cell migration and invasion by targeting forkhead box O1.
Zeng YB; Liang XH; Zhang GX; Jiang N; Zhang T; Huang JY; Zhang L; Zeng XC
Cancer Cell Int; 2016; 16():63. PubMed ID: 27486383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
